Kamenshchikov Nikolay O, Duong Nicolette, Berra Lorenzo
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634012 Tomsk, Russia.
Department of Anaesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Biomedicines. 2023 Apr 3;11(4):1085. doi: 10.3390/biomedicines11041085.
Perioperative organ injury remains a medical, social and economic problem in cardiac surgery. Patients with postoperative organ dysfunction have increases in morbidity, length of stay, long-term mortality, treatment costs and rehabilitation time. Currently, there are no pharmaceutical technologies or non-pharmacological interventions that can mitigate the continuum of multiple organ dysfunction and improve the outcomes of cardiac surgery. It is essential to identify agents that trigger or mediate an organ-protective phenotype during cardiac surgery. The authors highlight nitric oxide (NO) ability to act as an agent for perioperative protection of organs and tissues, especially in the heart-kidney axis. NO has been delivered in clinical practice at an acceptable cost, and the side effects of its use are known, predictable, reversible and relatively rare. This review presents basic data, physiological research and literature on the clinical application of NO in cardiac surgery. Results support the use of NO as a safe and promising approach in perioperative patient management. Further clinical research is required to define the role of NO as an adjunct therapy that can improve outcomes in cardiac surgery. Clinicians also have to identify cohorts of responders for perioperative NO therapy and the optimal modes for this technology.
围手术期器官损伤仍是心脏手术中的一个医学、社会和经济问题。术后出现器官功能障碍的患者在发病率、住院时间、长期死亡率、治疗费用及康复时间方面均有所增加。目前,尚无药物技术或非药物干预措施能够缓解多器官功能障碍的进展并改善心脏手术的结局。识别在心脏手术期间触发或介导器官保护表型的药物至关重要。作者强调了一氧化氮(NO)作为围手术期器官和组织保护剂的作用,尤其是在心脏-肾脏轴方面。NO已在临床实践中以可接受的成本应用,其使用的副作用已知、可预测、可逆且相对罕见。本文综述了NO在心脏手术临床应用的基础数据、生理学研究及文献。结果支持将NO作为围手术期患者管理中一种安全且有前景的方法。需要进一步的临床研究来明确NO作为辅助治疗在改善心脏手术结局方面的作用。临床医生还必须确定围手术期NO治疗的反应者群体以及该技术的最佳应用模式。